EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Longitudinal Assessment of Cognitive Development in 23 Patients With Mucopolysaccharidosis ( MPS ) Type II : Results of up to 14 Years of Follow‐Up

J Julia Holdorp iD, M E Michelle Kruijshaar iD, A A M Audrey Vollebregt, A B Andre Rietman iD, M R K Marianne Dijkstra iD, C Carina Klees iD, M Margreet Wagenmakers iD, A H P Annie Nguyen, E Esmee Oussoren iD, A T Ans van der Ploeg iD, J M P Hannerieke van den Hout iD

Journal of Inherited Metabolic Disease · 2026

DOI: 10.1002/jimd.70246 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Inherited Metabolic Disease, 2026. Verfasst von J Julia Holdorp und 10 weiteren Autor:innen. Beteiligte Einrichtung: Center for Lysosomal and Metabolic Diseases, Erasmus MC University Medical Center, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Mucopolysaccharidosis II, Cognition. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study investigated long‐term cognitive development and genotype–phenotype relationships in patients with Mucopolysaccharidosis Type II (MPS II). A nationwide prospective cohort study was conducted in the Netherlands with cognitive follow‐up since 2007. Patients were classified as neuronopathic or non‐neuronopathic based on iduronate‐2‐sulphatase ( IDS ) genotype; novel variants based on age and intelligence quotient (IQ). IQ and Mental Age (MA) were analysed individually and, using linear mixed‐effect models, at group level to compare trajectories by genotype and phenotype. Twenty‐three male patients (22 children, 1 adult) underwent 136 cognitive assessments, beginning at a median age of 2.9 years with a median follow‐up of 6.3 (range 0–13.5) years. IQ and MA trajectories significantly differed between neuronopathic and non‐neuronopathic patients ( p < 0.001). Non‐neuronopathic patients ( n = 5) showed normal or mildly impaired cognition. Neuronopathic patients ( n = 18) initially developed normally, then stagnated, plateaued, and declined; IQ fell below 70 at a median age of 4 years. Patients with deletions ( n = 3) experienced the earliest, most severe impairment ( p < 0.001), while those with other IDS variants showed more variable trajectories. Neurocognitive patterns diverge early in MPS II, highlighting the importance of understanding genotype‐specific developmental trajectories. This insight is essential for guiding timely brain‐targeted interventions, ideally initiated before neurocognitive decline begins.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mucopolysaccharidosis IICognitionHumansMaleChildChild, PreschoolAdolescentFollow-Up StudiesProspective StudiesLongitudinal StudiesIduronate SulfataseInfantPhenotypeGenotypeNetherlandsFemaleAdultIntelligenceIntelligence TestsGlycoproteins

Stichwörter der Autor:innen

Mucopolysaccharidosis Type IIenzyme replacement therapyiduronate‐2‐sulfatasenatural historyneurocognitive development

Substanzen

Iduronate SulfataseGlycoproteins

Autor:innen und Institutionen

  • Center for Lysosomal and Metabolic Diseases, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
  • Department of Paediatrics, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
  • Department of Child and Adolescent Psychiatry and Psychology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
  • Department of Internal Medicine, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
  • Department of Psychiatry, Erasmus MC University Medical Center, Rotterdam, the Netherlands.

ORCID-Profile: J Julia Holdorp, M E Michelle Kruijshaar, A B Andre Rietman, M R K Marianne Dijkstra, C Carina Klees, M Margreet Wagenmakers, E Esmee Oussoren, A T Ans van der Ploeg, J M P Hannerieke van den Hout

Zitieren

APA

Holdorp, J. J., Kruijshaar, M. E. M., Vollebregt, A. A. M. A., Rietman, A. B. A., Dijkstra, M. R. K. M., Klees, C. C., Wagenmakers, M. M., Nguyen, A. H. P. A., Oussoren, E. E., van der Ploeg, A. T. A., & van den Hout, J. M. P. H. (2026). Longitudinal Assessment of Cognitive Development in 23 Patients With Mucopolysaccharidosis ( MPS ) Type II : Results of up to 14 Years of Follow‐Up. Journal of Inherited Metabolic Disease. https://doi.org/10.1002/jimd.70246

Vancouver

Holdorp JJ, Kruijshaar MEM, Vollebregt AAMA, Rietman ABA, Dijkstra MRKM, Klees CC, et al. Longitudinal Assessment of Cognitive Development in 23 Patients With Mucopolysaccharidosis ( MPS ) Type II : Results of up to 14 Years of Follow‐Up. Journal of Inherited Metabolic Disease. 2026. doi:10.1002/jimd.70246

BibTeX
@article{Holdorp2026,
  author = {Holdorp, J Julia and Kruijshaar, M E Michelle and Vollebregt, A A M Audrey and Rietman, A B Andre and Dijkstra, M R K Marianne and Klees, C Carina and Wagenmakers, M Margreet and Nguyen, A H P Annie and Oussoren, E Esmee and van der Ploeg, A T Ans and van den Hout, J M P Hannerieke},
  title = {Longitudinal Assessment of Cognitive Development in 23 Patients With Mucopolysaccharidosis ( MPS ) Type II : Results of up to 14 Years of Follow‐Up},
  journal = {Journal of Inherited Metabolic Disease},
  year = {2026},
  doi = {10.1002/jimd.70246}
}
Kostenlos starten →